CASI Pharmaceuticals Inc. (CASI)
(Delayed Data from NSDQ)
$1.68 USD
-0.26 (-13.40%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $1.68 0.00 (0.00%) 4:46 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CASI 1.68 -0.26(-13.40%)
Will CASI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CASI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CASI
Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates
Indivior PLC (INDV) Tops Q2 Earnings and Revenue Estimates
CASI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q2
Other News for CASI
12 Health Care Stocks Moving In Monday's Intraday Session
FDA Approves IND Application for CASI's CID-103, Advancing AMR Treatment
CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft ...
Casi Pharmaceuticals announces FDA clearance of CID-103 IND application
CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)